34.03
-1(-2.85%)
Currency In USD
| Previous Close | 35.03 |
| Open | 34.87 |
| Day High | 34.78 |
| Day Low | 33.49 |
| 52-Week High | 60.37 |
| 52-Week Low | 29.59 |
| Volume | 1.61M |
| Average Volume | 933,450 |
| Market Cap | 3.22B |
| PE | -5.84 |
| EPS | -5.83 |
| Moving Average 50 Days | 36.01 |
| Moving Average 200 Days | 45.37 |
| Change | -1 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $392.73 as of June 01, 2025 at a share price of $34.03. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $488.94 as of June 01, 2025 at a share price of $34.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
GlobeNewswire Inc.
May 14, 2025 8:30 PM GMT
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report highlights efforts to transform the li
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
GlobeNewswire Inc.
May 07, 2025 9:00 PM GMT
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
GlobeNewswire Inc.
Apr 30, 2025 9:00 PM GMT
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today